Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Shorla Oncology Gets FDA Approval for TEPYLUTE for Breast and Ovarian Cancer
Details : FDA has approved the NDA for alkylating agent, TEPYLUTE (thiotepa), a ready-to-dilute infusion formulation to treat breast and ovarian cancer.
Brand Name : Tepylute
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2024
LOOKING FOR A SUPPLIER?